Home / CRL : NYSE

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does CRL make money? Does CRL have pricing power? What's the Earnings Whisper? Will CRL profit more as the business scales? What is CRL's management track record? Is CRL's current price justified?

Charles River Laboratories International, Inc.

$273.75 +$71.33 (+35.24%)

NYSE · 14 Sep 2026 16:44 UTC

Previous Close

$278.26

Day Range

$267.27$279.64

Year Range

$144.26$303.31

Market Cap

13.19B

AVG Volume

905.07K

Trailing/Forward PE

-56.56/21.5

PEG ratio

-4.53

Dividend Yield

Next Earnings Date

2026-11-04

Primary Exchange

New York Stock Exchange

Revenue (USD)

CRL Revenue (USD) by year
Period	Revenue (USD)
2025	4.02B
2024	4.05B
2023	4.13B
2022	3.98B
2021	3.54B
2020	2.92B
2019	2.62B
2018	2.27B
2017	1.86B
2016	1.68B

Net Income (USD)

CRL Net Income (USD) by year
Period	Net Income (USD)
2025	-144.34M
2024	10.3M
2023	474.62M
2022	486.23M
2021	390.98M
2020	364.3M
2019	252.02M
2018	226.37M
2017	123.36M
2016	154.76M

Operating Income (USD)

CRL Operating Income (USD) by year
Period	Operating Income (USD)
2025	428.82M
2024	227.35M
2023	617.26M
2022	650.98M
2021	589.86M
2020	432.73M
2019	351.15M
2018	331.38M
2017	288.19M
2016	237.42M

EBITDA (USD)

CRL EBITDA (USD) by year
Period	EBITDA (USD)
2025	410.84M
2024	581.14M
2023	1.03B
2022	986.15M
2021	820.16M
2020	768.47M
2019	563.06M
2018	507.23M
2017	457.89M
2016	377.29M

Cash Flows (USD)

CRL Cash Flows (USD) by year
Period	Cash Flows (USD)
2025	518.49M
2024	501.61M
2023	365.37M
2022	294.91M
2021	532.03M
2020	380.01M
2019	340.42M
2018	301.09M
2017	233.83M
2016	243.03M

EPS (USD)

CRL EPS (USD) by year
Period	EPS (USD)
2025	-2.96
2024	0.15
2023	9.21
2022	9.47
2021	7.6
2020	7.2
2019	5.06
2018	4.61
2017	2.54
2016	3.23

Expenses (USD)

CRL Expenses (USD) by year
Period	Expenses (USD)
2025	953.72M
2024	983.97M
2023	1.07B
2022	989.83M
2021	848.69M
2020	695.5M
2019	658.14M
2018	583.91M
2017	454.15M
2016	422.84M

Cash & Debt (USD)

CRL Cash & Debt (USD) by year
Period	Cash & Debt (USD)
2025	213.77M
2024	194.61M
2023	276.77M
2022	233.91M
2021	245.24M
2020	229.45M
2019	238.96M
2018	195.44M
2017	163.79M
2016	117.63M

Debt ratios

CRL Debt ratios by year
Period	Debt ratios
2025	0.95
2024	0.74
2023	0.77
2022	0.91
2021	1.11
2020	0.84
2019	0.94
2018	0.91

Margins

CRL Margins by year
Period	Margins
2025	32.91%
2024	32.88%
2023	36.39%
2022	36.79%
2021	37.7%
2020	36.72%
2019	36.56%
2018	37.07%
2017	37.75%
2016	38.46%

Return on Capital

CRL Return on Capital by year
Period	Return on Capital
2025	-4.49%
2024	0.29%
2023	12.97%
2022	16.08%
2021	15.08%
2020	16.99%
2019	15.12%
2018	16.91%
2017	11.59%
2016	18.13%

Shares Outstanding

CRL Shares Outstanding by year
Period	Shares Outstanding
2025	49.22M
2024	51.14M
2023	51.31M
2022	50.91M
2021	50.47M
2020	49.75M
2019	48.88M
2018	48.14M
2017	46.75M
2016	47.19M

Book Value Per Share (USD)

CRL Book Value Per Share (USD) by year
Period	Book Value Per Share (USD)
2025	65.25
2024	68.6
2023	71.31
2022	59.39
2021	51.36
2020	43.09
2019	34.1
2018	27.8
2017	22.76
2016	18.09

Total Assets (USD)

CRL Total Assets (USD) by year
Period	Total Assets (USD)
2025	7.14B
2024	7.53B
2023	8.2B
2022	7.6B
2021	7.02B
2020	5.49B
2019	4.69B
2018	3.86B
2017	2.93B
2016	2.71B

Employee Count

CRL Employee Count by year
Period	Employee Count
2025	19.7K
2024	20.1K
2023	21.8K
2022	21.4K
2021	20K
2020	18.4K
2019	17.1K
2018	14.7K
2017	11.8K
2016	11K

PE Ratio

CRL PE Ratio by year
Period	PE Ratio
May 25	588.31
Apr 25	569.44
Apr 25	526.68
Apr 25	495.39
Apr 25	679.89
Mar 25	772.51
Mar 25	830.76
Mar 25	849.44
Mar 25	873.67
Feb 25	820.98
Feb 25	809.61
Feb 25	18.91
Feb 25	20.38
Jan 25	20.5
Jan 25	20.53
Jan 25	20.34
Jan 25	23.16
Jan 25	23.12
Dec 24	23.16
Dec 24	23.11
Dec 24	23.7
Dec 24	23.86
Nov 24	24.77
Nov 24	24.36
Nov 24	23.36
Nov 24	26.8
Nov 24	21.6
Oct 24	21.74
Oct 24	23.61
Oct 24	23.04
Oct 24	22.77
Sep 24	23.68
Sep 24	24.57
Sep 24	23.71
Sep 24	22.44
Aug 24	23.61
Aug 24	24.51
Aug 24	24.1
Aug 24	23.99
Aug 24	27.38
Jul 24	27.37
Jul 24	25.58
Jul 24	25.34
Jul 24	23.4
Jun 24	24.21
Jun 24	24.8
Jun 24	24.55
Jun 24	25.18
May 24	24.43
May 24	25.46
May 24	25.98
May 24	26.74
May 24	25.24
Apr 24	24.76
Apr 24	24.52
Apr 24	26.09
Apr 24	27.36
Mar 24	29.29
Mar 24	29.47
Mar 24	28
Mar 24	28.86
Mar 24	28.58
Feb 24	26.78
Feb 24	26.48
Feb 24	23.99
Feb 24	23.56
Jan 24	23.78
Jan 24	22.89
Jan 24	22.84
Jan 24	24.17
Dec 23	25.53
Dec 23	25.51
Dec 23	24.92
Dec 23	22.08
Dec 23	21.78
Nov 23	21.26
Nov 23	20.41
Nov 23	18.57
Nov 23	19.25
Oct 23	18.26
Oct 23	19.62
Oct 23	20.21
Oct 23	20.47
Sep 23	20.74
Sep 23	21.12
Sep 23	22
Sep 23	21.13
Sep 23	22.18
Aug 23	21.2
Aug 23	21.05
Aug 23	22.69
Aug 23	21.39
Jul 23	21.76
Jul 23	21.33
Jul 23	21.46
Jul 23	21.39
Jun 23	21.73
Jun 23	21.48
Jun 23	21.71
Jun 23	20.44

Free Cash Flow Yield

CRL Free Cash Flow Yield by year
Period	Free Cash Flow Yield
Sep 26	2.75%
Sep 26	2.65%
Aug 26	2.62%
Aug 26	2.59%
Aug 26	2.73%
Aug 26	2.86%
Jul 26	3.44%
Jul 26	3.53%
Jul 26	3.56%
Jul 26	3.42%
Jul 26	3.47%
Jun 26	3.7%
Jun 26	4.32%
Jun 26	4.26%
Jun 26	4.41%
May 26	4.42%
May 26	4.99%
May 26	5.3%
May 26	4.5%
May 26	6.35%
Apr 26	6.2%
Apr 26	5.73%
Apr 26	6%
Apr 26	6.06%
Mar 26	6.62%
Mar 26	6.86%
Mar 26	6.78%
Mar 26	6.04%
Feb 26	5.9%
Feb 26	6.24%
Feb 26	6.85%
Feb 26	5.84%
Jan 26	5.25%
Jan 26	5.03%
Jan 26	5.03%
Jan 26	5%
Jan 26	5.46%
Dec 25	5.42%
Dec 25	5.61%
Dec 25	5.72%
Dec 25	5.99%
Nov 25	6.2%
Nov 25	6.59%
Nov 25	6.58%
Nov 25	6.57%
Oct 25	6.54%
Oct 25	5.97%
Oct 25	6.59%
Oct 25	7.05%
Oct 25	6.64%
Sep 25	7.92%
Sep 25	7.57%
Sep 25	7.7%
Sep 25	7.18%
Aug 25	7.21%
Aug 25	7.27%
Aug 25	7.51%
Aug 25	7.91%
Aug 25	6.66%
Jul 25	6.28%
Jul 25	7.19%
Jul 25	6.97%
Jul 25	7.07%
Jun 25	7.41%
Jun 25	7.54%
Jun 25	7.44%
Jun 25	7.68%
May 25	8.19%
May 25	8.13%
May 25	7.88%
May 25	8.01%
May 25	8.28%
Apr 25	8.55%
Apr 25	9.25%
Apr 25	9.83%
Apr 25	7.17%
Mar 25	6.31%
Mar 25	5.86%
Mar 25	5.73%
Mar 25	5.58%
Feb 25	5.93%
Feb 25	6.02%
Feb 25	7.18%
Feb 25	6.66%
Jan 25	6.62%
Jan 25	6.61%
Jan 25	6.67%
Jan 25	5.86%
Jan 25	5.87%
Dec 24	5.86%
Dec 24	5.87%
Dec 24	5.73%
Dec 24	5.69%
Nov 24	5.48%
Nov 24	5.57%
Nov 24	5.81%
Nov 24	5.06%
Nov 24	5.22%
Oct 24	5.19%
Oct 24	4.78%

Price to Sales

CRL Price to Sales by year
Period	Price to Sales
Sep 26	3.37
Sep 26	3.5
Aug 26	3.53
Aug 26	3.58
Aug 26	3.4
Aug 26	3.24
Jul 26	2.83
Jul 26	2.75
Jul 26	2.73
Jul 26	2.84
Jul 26	2.8
Jun 26	2.62
Jun 26	2.25
Jun 26	2.28
Jun 26	2.2
May 26	2.2
May 26	1.95
May 26	1.83
May 26	2.16
May 26	2.03
Apr 26	2.08
Apr 26	2.25
Apr 26	2.15
Apr 26	2.13
Mar 26	1.95
Mar 26	1.88
Mar 26	1.91
Mar 26	2.14
Feb 26	2.19
Feb 26	2.07
Feb 26	1.97
Feb 26	2.31
Jan 26	2.57
Jan 26	2.69
Jan 26	2.69
Jan 26	2.7
Jan 26	2.48
Dec 25	2.49
Dec 25	2.41
Dec 25	2.36
Dec 25	2.25
Nov 25	2.18
Nov 25	2.05
Nov 25	2.05
Nov 25	2.06
Oct 25	2.2
Oct 25	2.4
Oct 25	2.18
Oct 25	2.04
Oct 25	2.16
Sep 25	1.81
Sep 25	1.9
Sep 25	1.87
Sep 25	2
Aug 25	1.99
Aug 25	1.97
Aug 25	1.91
Aug 25	1.81
Aug 25	2.1
Jul 25	2.23
Jul 25	1.95
Jul 25	2.01
Jul 25	1.98
Jun 25	1.89
Jun 25	1.86
Jun 25	1.88
Jun 25	1.82
May 25	1.71
May 25	1.72
May 25	1.78
May 25	1.75
May 25	1.5
Apr 25	1.45
Apr 25	1.34
Apr 25	1.26
Apr 25	1.73
Mar 25	1.96
Mar 25	2.11
Mar 25	2.16
Mar 25	2.22
Feb 25	2.09
Feb 25	2.06
Feb 25	1.92
Feb 25	2.07
Jan 25	2.09
Jan 25	2.09
Jan 25	2.07
Jan 25	2.36
Jan 25	2.35
Dec 24	2.36
Dec 24	2.35
Dec 24	2.41
Dec 24	2.43
Nov 24	2.52
Nov 24	2.48
Nov 24	2.38
Nov 24	2.73
Nov 24	2.29
Oct 24	2.3
Oct 24	2.5

EV/EBITDA

CRL EV/EBITDA by year
Period	EV/EBITDA
Sep 26	74.06
Sep 26	76.31
Aug 26	76.97
Aug 26	77.78
Aug 26	74.45
Aug 26	71.69
Jul 26	49.03
Jul 26	48.03
Jul 26	47.65
Jul 26	49.18
Jul 26	48.72
Jun 26	46.21
Jun 26	41.03
Jun 26	41.45
Jun 26	40.41
May 26	40.3
May 26	36.86
May 26	35.27
May 26	39.78
May 26	26.8
Apr 26	27.28
Apr 26	28.97
Apr 26	27.98
Apr 26	27.77
Mar 26	26.01
Mar 26	25.34
Mar 26	25.56
Mar 26	27.84
Feb 26	28.32
Feb 26	27.18
Feb 26	20.07
Feb 26	22.72
Jan 26	24.75
Jan 26	25.62
Jan 26	25.63
Jan 26	25.74
Jan 26	23.98
Dec 25	24.1
Dec 25	23.47
Dec 25	23.09
Dec 25	22.26
Nov 25	21.67
Nov 25	20.67
Nov 25	20.68
Nov 25	20.71
Oct 25	21.68
Oct 25	23.25
Oct 25	21.53
Oct 25	20.46
Oct 25	21.42
Sep 25	18.75
Sep 25	19.38
Sep 25	19.15
Sep 25	20.18
Aug 25	20.12
Aug 25	19.98
Aug 25	19.5
Aug 25	18.76
Aug 25	20.54
Jul 25	21.47
Jul 25	19.39
Jul 25	19.84
Jul 25	19.63
Jun 25	18.97
Jun 25	18.73
Jun 25	18.92
Jun 25	18.48
May 25	17.64
May 25	17.74
May 25	18.13
May 25	17.93
May 25	14.78
Apr 25	14.44
Apr 25	13.68
Apr 25	13.13
Apr 25	16.4
Mar 25	18.04
Mar 25	19.07
Mar 25	19.4
Mar 25	19.83
Feb 25	18.9
Feb 25	18.7
Feb 25	10.46
Feb 25	11.07
Jan 25	11.12
Jan 25	11.14
Jan 25	11.06
Jan 25	12.23
Jan 25	12.22
Dec 24	12.23
Dec 24	12.21
Dec 24	12.46
Dec 24	12.53
Nov 24	12.9
Nov 24	12.73
Nov 24	12.32
Nov 24	13.75
Nov 24	11.91
Oct 24	11.97
Oct 24	12.78

Price/Operating Cashflow

CRL Price/Operating Cashflow by year
Period	Price/Operating Cashflow
Sep 26	23.18
Sep 26	24.03
Aug 26	24.28
Aug 26	24.59
Aug 26	23.32
Aug 26	22.28
Jul 26	18.75
Jul 26	18.27
Jul 26	18.09
Jul 26	18.82
Jul 26	18.6
Jun 26	17.4
Jun 26	14.92
Jun 26	15.12
Jun 26	14.62
May 26	14.57
May 26	12.93
May 26	12.16
May 26	14.32
May 26	11.06
Apr 26	11.33
Apr 26	12.27
Apr 26	11.72
Apr 26	11.6
Mar 26	10.62
Mar 26	10.25
Mar 26	10.37
Mar 26	11.64
Feb 26	11.91
Feb 26	11.27
Feb 26	10.59
Feb 26	12.42
Jan 26	13.82
Jan 26	14.42
Jan 26	14.43
Jan 26	14.51
Jan 26	13.29
Dec 25	13.37
Dec 25	12.94
Dec 25	12.67
Dec 25	12.1
Nov 25	11.7
Nov 25	11.01
Nov 25	11.02
Nov 25	11.03
Oct 25	11.24
Oct 25	12.3
Oct 25	11.14
Oct 25	10.43
Oct 25	11.07
Sep 25	9.27
Sep 25	9.7
Sep 25	9.54
Sep 25	10.24
Aug 25	10.19
Aug 25	10.1
Aug 25	9.78
Aug 25	9.28
Aug 25	10.89
Jul 25	11.55
Jul 25	10.08
Jul 25	10.4
Jul 25	10.26
Jun 25	9.79
Jun 25	9.62
Jun 25	9.76
Jun 25	9.44
May 25	8.85
May 25	8.92
May 25	9.2
May 25	9.06
May 25	8.25
Apr 25	7.98
Apr 25	7.38
Apr 25	6.94
Apr 25	9.53
Mar 25	10.83
Mar 25	11.65
Mar 25	11.91
Mar 25	12.25
Feb 25	11.51
Feb 25	11.35
Feb 25	9.81
Feb 25	10.57
Jan 25	10.64
Jan 25	10.65
Jan 25	10.55
Jan 25	12.01
Jan 25	11.99
Dec 24	12.02
Dec 24	11.99
Dec 24	12.29
Dec 24	12.38
Nov 24	12.85
Nov 24	12.64
Nov 24	12.12
Nov 24	13.9
Nov 24	12.44
Oct 24	12.52
Oct 24	13.6

Price to Book

CRL Price to Book by year
Period	Price to Book
Sep 26	4.74
Sep 26	4.92
Aug 26	4.97
Aug 26	5.03
Aug 26	4.77
Aug 26	4.56
Jul 26	3.81
Jul 26	3.71
Jul 26	3.68
Jul 26	3.82
Jul 26	3.78
Jun 26	3.53
Jun 26	3.03
Jun 26	3.07
Jun 26	2.97
May 26	2.96
May 26	2.63
May 26	2.47
May 26	2.91
May 26	2.54
Apr 26	2.6
Apr 26	2.82
Apr 26	2.69
Apr 26	2.67
Mar 26	2.44
Mar 26	2.35
Mar 26	2.38
Mar 26	2.67
Feb 26	2.74
Feb 26	2.59
Feb 26	2.3
Feb 26	2.7
Jan 26	3
Jan 26	3.13
Jan 26	3.13
Jan 26	3.15
Jan 26	2.89
Dec 25	2.9
Dec 25	2.81
Dec 25	2.75
Dec 25	2.63
Nov 25	2.54
Nov 25	2.39
Nov 25	2.39
Nov 25	2.4
Oct 25	2.6
Oct 25	2.85
Oct 25	2.58
Oct 25	2.41
Oct 25	2.56
Sep 25	2.15
Sep 25	2.25
Sep 25	2.21
Sep 25	2.37
Aug 25	2.36
Aug 25	2.34
Aug 25	2.27
Aug 25	2.15
Aug 25	2.61
Jul 25	2.77
Jul 25	2.41
Jul 25	2.49
Jul 25	2.46
Jun 25	2.35
Jun 25	2.31
Jun 25	2.34
Jun 25	2.26
May 25	2.12
May 25	2.14
May 25	2.2
May 25	2.17
May 25	1.73
Apr 25	1.67
Apr 25	1.55
Apr 25	1.45
Apr 25	2
Mar 25	2.27
Mar 25	2.44
Mar 25	2.49
Mar 25	2.56
Feb 25	2.41
Feb 25	2.38
Feb 25	2.04
Feb 25	2.2
Jan 25	2.21
Jan 25	2.22
Jan 25	2.2
Jan 25	2.5
Jan 25	2.49
Dec 24	2.5
Dec 24	2.49
Dec 24	2.56
Dec 24	2.58
Nov 24	2.67
Nov 24	2.63
Nov 24	2.52
Nov 24	2.89
Nov 24	2.47
Oct 24	2.49
Oct 24	2.7

No video analysis for this stock yet. Request one from our team.

News: CRL

seekingalpha.com · 14 Sep 2026

Charles River Laboratories International, Inc. (CRL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

gurufocus.com · 11 Sep 2026

Charles River Laboratories to Present at Morgan Stanley and Baird Conferences

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at two upcoming investor conferences, including:Morgan Stanley 2

businesswire.com · 11 Sep 2026

Charles River Laboratories to Present at Morgan Stanley and Baird Conferences

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories to Present at Morgan Stanley and Baird Conferences.

defenseworld.net · 10 Sep 2026

Amundi Sells 360,913 Shares of Charles River Laboratories International, Inc. $CRL

Amundi trimmed its position in Charles River Laboratories International, Inc. (NYSE: CRL) by 46.7% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 412,402 shares of the medical research company's stock after selling 360,913 shares during the period.

fool.com · 8 Sep 2026

Does iShares Pharma ETF Offer Superior Returns to Invesco's Equal Weight Healthcare Fund?

IHE's concentrated pharma holdings delivered 50% returns over one year, while RSPH's equal-weight healthcare approach generated 29%. Risk profiles differ sharply too.

businesswire.com · 8 Sep 2026

Charles River Modernizes Endosafe® Endotoxin Testing Cartridge Manufacturing with Fully Automated Production Suite

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) has successfully implemented its Endosafe® Cartridge Technology Automated Manufacturing Suite, a significant advancement in bacterial endotoxin testing cartridge production that expands in-process inspection and digital traceability, strengthens manufacturing controls and increases production capacity. Reaching full operational capacity in Q3 2026, the automated suite is a major investment in advanced.

zacks.com · 4 Sep 2026

Charles River (CRL) Up 10.5% Since Last Earnings Report: Can It Continue?

Charles River (CRL) reported earnings 30 days ago. What's next for the stock?

zacks.com · 1 Sep 2026

Is This the Right Time to Add CRL Stock to Your Portfolio?

Charles River's improving DSA demand and strategic investments support growth, but uneven recovery and NHP cost volatility remain key risks.

AI Analysis

Charles River Laboratories International, Inc.

Video analysis: CRL

News: CRL

Charles River Laboratories International, Inc. (CRL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Charles River Laboratories to Present at Morgan Stanley and Baird Conferences

Charles River Laboratories to Present at Morgan Stanley and Baird Conferences

Amundi Sells 360,913 Shares of Charles River Laboratories International, Inc. $CRL

Does iShares Pharma ETF Offer Superior Returns to Invesco's Equal Weight Healthcare Fund?

Charles River Modernizes Endosafe® Endotoxin Testing Cartridge Manufacturing with Fully Automated Production Suite

Charles River (CRL) Up 10.5% Since Last Earnings Report: Can It Continue?

Is This the Right Time to Add CRL Stock to Your Portfolio?

Similar companies